Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity

Guruprasad P. Aithal, Lesley Ramsay, Ann K. Daly, Nhareet Sonchit, Julian B. S. Leathart, Graeme Alexander, J. Gerald Kenna, John Caldwell, Christopher P. Day – 26 April 2004 – Diclofenac is a nonsteroidal anti‐inflammatory drug that causes rare but serious hepatotoxicity, the mechanism of which is unclear. The purpose of the present study was to explore the potential role played by the immune processes.

Angiogenesis in chronic inflammatory liver disease

Jesús Medina, Alicia G. Arroyo, Francisco Sánchez‐Madrid, Ricardo Moreno‐Otero – 26 April 2004 – Intrahepatic hypoxia may occur during the inflammatory and fibrotic processes that characterize several chronic liver diseases of viral and autoimmune origin. As a consequence, new vascular structures are formed to provide oxygen and nutrients. Angiogenesis involves a tightly regulated network of cellular and molecular mechanisms that result in the formation of functional vessels.

Activation of hepatic Nrf2 in vivo by acetaminophen in CD‐1 mice

Christopher E. P. Goldring, Neil R. Kitteringham, Robert Elsby, Laura E. Randle, Yuri N. Clement, Dominic P. Williams, Michael McMahon, John D. Hayes, Ken Itoh, Masayuki Yamamoto, B. Kevin Park – 26 April 2004 – The transcription factor NF‐E2‐related factor 2 (Nrf2) plays an essential role in the mammalian response to chemical and oxidative stress through induction of hepatic phase II detoxification enzymes and regulation of glutathione (GSH).

Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury

Meagan J. Walsh, Daina M. Vanags, Andrew D. Clouston, Michelle M. Richardson, David M. Purdie, Julie R. Jonsson, Elizabeth E. Powell – 26 April 2004 – Steatosis is increasingly recognized as a cofactor influencing the progression of fibrosis in chronic hepatitis C; however, the mechanisms by which it contributes to liver injury remain uncertain.

In vitro comparison of the molecular adsorbent recirculation system (MARS) and single‐pass albumin dialysis (SPAD)

Igor M. Sauer, Max Goetz, Ingo Steffen, Gesa Walter, Daniel C. Kehr, Ruth Schwartlander, Yoon J. Hwang, Andreas Pascher, Joerg C. Gerlach, Peter Neuhaus – 26 April 2004 – The detoxification capacities of single‐pass albumin dialysis (SPAD), the molecular adsorbents recirculation system, (MARS) and continuous veno‐venous hemodiafiltration (CVVHDF) were compared in vitro. In each experiment 4,100 mL of toxin‐loaded human plasma was processed for 6.5 hours. MARS treatment (n = 6) was undertaken in combination with CVVHDF.

2‐acetylaminofluorene dose‐dependent differentiation of rat oval cells into hepatocytes: Confocal and electron microscopic studies

Sándor Paku, Peter Nagy, László Kopper, Snorri S. Thorgeirsson – 26 April 2004 – The 2‐acetylaminofluorene (AAF)/partial hepatectomy (PH) model is one of the most extensively studied experimental systems for oval cell proliferation and differentiation. We have previously described the oval cells as forming ductular structures surrounded by basement membrane, representing extensions of the canals of Hering. Herein we analyze the differentiation of oval cells into hepatocytes after varying degrees of liver damage induced by AAF.

Subscribe to